Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | PIM3 | Q86V86 | 1/20 | 0.34 |
| ▸ | NPC1 | O15118 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4553102 | 1.00 | ALDH1A1 (0.37) | ALDH1A1GAAL3MBTL1PIM3NPC1 | |
| SCHEMBL965488 | 0.91 | POLB (0.34) | PIM3SMN1; SMN2 | |
| SCHEMBL964065 | 0.87 | PIM3 (0.43) | ALDH1A1GAAL3MBTL1PIM3NPC1 | |
| SCHEMBL964067 | 0.87 | PIM3 (0.43) | ALDH1A1GAAL3MBTL1PIM3NPC1 | |
| SCHEMBL965490 | 0.85 | PIM3 (0.32) | PIM3SMN1; SMN2MCL1 | |
| SCHEMBL965489 | 0.85 | PIM3 (0.32) | PIM3SMN1; SMN2MCL1 | |
| SCHEMBL4553930 | 0.84 | ALDH1A1 (0.40) | ALDH1A1GAAL3MBTL1PIM3NPC1 | |
| SCHEMBL4553929 | 0.84 | ALDH1A1 (0.40) | ALDH1A1GAAL3MBTL1PIM3NPC1 | |
| SCHEMBL966513 | 0.83 | ALDH1A1 (0.44) | ALDH1A1GAAL3MBTL1NPC1RAB9A | |
| SCHEMBL966514 | 0.83 | ALDH1A1 (0.44) | ALDH1A1GAAL3MBTL1NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2118066-A1 | FUSED RING COMPOUNDS AS PARTIAL AGONISTS OF PPAR-GAMMA | Takeda Pharmaceutical Company Limited (JP) | 2009-11-18 | — | — | EP | disclosed |
| WO-2008099794-A1 | FUSED RING COMPOUNDS AS PARTIAL AGONISTS OF PPAR-GAMMA | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-08-21 | — | — | WO | disclosed |
| US-20080194617-A1 | Fused ring compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-08-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080194617-A1 | Fused ring compound | SLC5A1, SLC5A2, GPR119 | ALDH1A1 421/4885GAA 76/4885L3MBTL1 2943/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.